Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$12.20 USD
-0.03 (-0.25%)
Updated May 24, 2024 04:00 PM ET
After-Market: $12.21 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MLYS 12.20 -0.03(-0.25%)
Will MLYS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for MLYS
Commit To Buy Mineralys Therapeutics At $10, Earn 19.5% Annualized Using Options
Bank of America Securities Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS) Q1 2024 Earnings Call Transcript
Mineralys Therapeutics price target lowered by $1 at Wells Fargo, here's why
Mineralys Therapeutics: Strong Buy on Upcoming ADVANCE Trial Results and Robust Financial Health